Neuroendocrine carcinoma
Therapeutic area
Oncology
Rare disease
No
- Definition
- A malignant neuroendocrine neoplasm composed of cells containing secretory granules that stain positive for NSE and chromogranin. The neoplastic cells are often round and form clusters or trabecular sheets. Representative examples are small cell carcinoma, large cell neuroendocrine carcinoma, and Merkel cell carcinoma.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Neuroendocrine carcinoma
- Therapeutic area
- Oncology
- neuroendocrine carcinoma
- NEC
- neuroendocrine cancer
- neuroendocrine carcinoma
- Severity
- Severe
- Endocrinology
- Oncology
- MONDO ID
- MONDO:0002120
- Parent condition
- MONDO:0004993
Related records
Broader conditions (14)
- Cancer
- Cancer or benign tumor
- Carcinoma
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Endocrine gland neoplasm
- Endocrine system disorder
- Epithelial neoplasm
- Human disease
- Malignant endocrine neoplasm
- Neoplasm
- Neoplastic disease or syndrome
- Neuroendocrine neoplasm
Narrower conditions (47)
- Ampulla of vater small cell neuroendocrine carcinoma
- Anal canal neuroendocrine neoplasm
- Bartholin gland small cell carcinoma
- Breast large cell neuroendocrine carcinoma
- Cervical large cell neuroendocrine carcinoma
- Cervical small cell carcinoma
- Colon small cell neuroendocrine carcinoma
- Combined lung carcinoma
- Combined small cell lung carcinoma
- Cutaneous neuroendocrine carcinoma
- Endometrial small cell carcinoma
- Esophageal small cell neuroendocrine carcinoma
- Extrahepatic bile duct small cell adenocarcinoma
- Familial medullary thyroid carcinoma
- Gallbladder small cell neuroendocrine carcinoma
- Gastric small cell neuroendocrine carcinoma
- Goblet cell carcinoma
- Hypercalcemic type ovarian small cell carcinoma
- Large cell neuroendocrine carcinoma
- Laryngeal small cell carcinoma
Trials (165)
- 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial
- 5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors
- 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
- 68Ga-DOTATATE PET Scan in Neuroendocrine Cancer
- 68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)
- A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours
- A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma
- A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
- A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
- A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma
- A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma
- A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC
- A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers
- A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors
- A Phase II Clinical Study of SHR-A1904 Monotherapy in Second-Line or Later Treatment of Advanced Neuroendocrine Carcinoma
- A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
- A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung
- A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.
- A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
- A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate
Drugs in development (59)
- .ALPHA.-pyrrolidinononanophenone Phase 1
- Atezolizumab Phase 2
- Atiprimod Phase 2
- Avelumab Phase 2
- Bevacizumab Phase 2
- Cabozantinib Phase 2
- Cabozantinib S-malate Phase 2
- Camrelizumab Phase 2
- Capecitabine Phase 2
- Carboplatin Phase 2
- Carfilzomib Phase 2
- Cisplatin Phase 2
- Copper oxodotreotide CU-64 Phase 2
- Docetaxel Phase 2
- Dordaviprone Phase 2
- Dotamtate Phase 1
- Dotamtate PB-212 Phase 1
- Durvalumab Phase 2
- Edotreotide Phase 2
- Etoposide Phase 2
Other linked drugs (4)
- Edotreotide gallium GA-68
- Iobenguane I 123
- Retifanlimab
- Tetraxetan